PURE Engagement, the industry benchmark for patient and provider support program performance, today announced the 2025 PURE Award winners across key therapeutic areas. The awards recognize manufacturers delivering best-in-class patient access, affordability, education, and service—backed by the voices of patients, healthcare professionals, and support staff.

2025 Winners by Category

• Oncology:Pfizer (second consecutive year for win; Merck was a close runner-up in this highly competitive category)
• Neurology:AbbVie (driven by support for migraine; Pfizer runner-up)
• Rheumatology:AbbVie (led by Rinvoq/Skyrizi support)
• Dermatology: AbbVie and Sanofi/Regeneron (shared first place; tied assessment score)
• Gastroenterology:AbbVie (led by Rinvoq/Skyrizi support)
• Respiratory:Sanofi/Regeneron (Dupixent, ahead of Merck)
• Hemophilia:Pfizer (strong name recognition and consistently positive feedback, ahead of Genentech and Sanofi)

Beyond the best-in-class winners by therapeutic area, several additional companies merit special recognition.

Additional Recognitions

• Oncology Biotech: Genmab (top among mid-sized oncology peers; standout digital solutions)
• Multiple Sclerosis: Genentech (best in MS; strong technology and patient assistance program)
• Parkinson’s: Acadia (top spot driven by responsiveness and rapid issue resolution)

“Each year, the PURE Awards spotlight programs that set the pace on speed, clarity, and compassion,” said Jens Kulstad, Head of PURE. “Oncology once again proved to be the most hotly contested field, with Pfizer narrowly topping Merck for a second straight year. AbbVie’s sustained excellence across neurology and immunology—fueled by standout support for migraine, and excellent field support for Rinvoq and Skyrizi in immunology —demonstrates how consistent execution earns trust. Sanofi/Regeneron’s Dupixent leadership in respiratory and dermatology underscores the impact of integrated, cross-stakeholder support.”

How the PURE Awards Are Determined

The awards are based on PURE Engagement, an annual assessment that gathers structured feedback from consistent users (physicians, nurses, pharmacists, and administrative staff) across private practice, hospital systems, and academic centers. In 2025, PURE collected insights from physicians and support staff providing over 10,000 ratings covering over 50 pharmaceutical manufacturers, evaluating performance and identifying improvement opportunities across dimensions such as awareness and enrollment, responsiveness and turnaround times, copay and affordability support, case management, field reimbursement, digital experience, caregiver support, and policy education.

“PURE doesn’t just rate performance—we provide actionable, data-driven guidance to help teams invest where it matters most,” Kulstad added.